Clindamycin Plus Vancomycin Versus Linezolid for Treatment of Necrotizing Soft Tissue Infection

• Published in: Open forum infectious diseases Vol. 10; no. 6; p. ofad258
• Main Authors: Dorazio, Joshua, Chiappelli, Abby L, Shields, Ryan K, Tsai, Y Vivian, Skinker, Peyton, Nabozny, Michael J, Bauza, Graciela, Forsythe, Raquel, Rosengart, Matthew R, Gunn, Scott R, Marini, Rachel, Clarke, Lloyd, Falcione, Bonnie, Ludwig, Justin, McCreary, Erin K
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.06.2023
• Subjects: Editor's Choice; Major; surgical debridement; NSTI; piperacillin-tazobactam; life-threatening infection
• ISSN: 2328-8957; 2328-8957
• DOI: 10.1093/ofid/ofad258

Abstract Background Necrotizing soft tissue infections (NSTIs) are life-threatening infections. The aim of this study is to evaluate the safety of clindamycin plus vancomycin versus linezolid as empiric treatment of NSTIs. Methods This was a retrospective, single-center, quasi-experimental study of patients admitted from 1 June 2018 to 30 June 2019 (preintervention) and 1 May 2020 to 15 October 2021 (postintervention). Patients who received surgical management within 24 hours of NSTI diagnosis and at least 1 dose of linezolid or clindamycin were included. The primary endpoint was death at 30 days. The secondary outcomes included rates of acute kidney injury (AKI) and Clostridioides difficile infection (CDI). Results A total of 274 patients were identified by admission diagnosis code for NSTI or Fournier gangrene; 164 patients met the inclusion criteria. Sixty-two matched pairs were evaluated. There was no difference in rates of 30-day mortality (8.06% vs 6.45%; hazard ratio [HR], 1.67 [95% confidence interval {CI}, .32–10.73]; P = .65). There was no difference in CDI (6.45% vs 1.61%; HR, Infinite [Inf], [95% CI, .66–Inf]; P = .07) but more AKI in the preintervention group (9.68% vs 1.61%; HR, 6 [95% CI, .73–276]; P = .05). Conclusions In this small, retrospective, single-center, quasi-experimental study, there was no difference in 30-day mortality in patients receiving treatment with clindamycin plus vancomycin versus linezolid in combination with standard gram-negative and anaerobic therapy and surgical debridement for the treatment of NSTIs. A composite outcome of death, AKI, or CDI within 30 days was more common in the clindamycin plus vancomycin group. In this retrospective, quasi-experimental study, there was no difference in 30-day mortality in patients receiving treatment with clindamycin plus vancomycin versus linezolid in combination with standard gram-negative and anaerobic therapy and surgical debridement for the treatment of necrotizing soft tissue infections.